A
8.25
0.24 (3.00%)
| Previous Close | 8.01 |
| Volume | 5,475 |
| Price / Earnings (Forward) | 15.15 |
| Price / Sales | 18.42 |
| 52 Weeks Range |
| Profit Margin | -7.83% |
| Operating Margin (TTM) | 49.53% |
| Diluted EPS (TTM) | -2.26 |
| Quarterly Revenue Growth (YOY) | 258.80% |
| Current Ratio (MRQ) | 0.570 |
| Operating Cash Flow (TTM) | -67.24 M |
| Levered Free Cash Flow (TTM) | -62.49 M |
| Return on Assets (TTM) | -1.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Atara Biotherapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.96 |
Select this tab to load the latest available analysis.
|
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.44% |
| % Held by Institutions | 51.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Staley Capital Advisers Inc | 30 Jun 2026 | 50,000 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |